Home › Compare › CLKTF vs ABBV
CLKTF yields 20000000.00% · ABBV yields 3.06%● Live data
📍 CLKTF pulled ahead of the other in Year 1
Combined, CLKTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CLKTF + ABBV for your $10,000?
CalciTech Ltd. develops and commercializes synthetic calcium carbonate (SCC) in Europe. It produces SCC from waste lime and air polluting carbon dioxide. SCC is a white pigment that is used in various industrial applications, including paper, polymers, paints, foods, and pharmaceuticals. The company offers three SCC products targeting the paper industry, which comprise CalciLS, which is designed to maximize light scattering; CalciSG that is designed to provide a gloss coating for premium grade printing and writing papers; and CalciRG, a performance-enhancing additive targeted at the rotogravure market. It also provides CalciSP, a non-paper product targeted at the food, pharmaceutical, and cosmetics industries; and CalciRC, which is targeted at polymer applications, such as plastics, sealants, rubber, and adhesives. The company was formerly known as Kemgas Ltd. and changed its name to CalciTech Ltd. in July 2000 to reflect change in business to the production and sale of SCC. CalciTech Ltd. was founded in 1978 and is based in Geneva, Switzerland.
Full CLKTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.